dr. selçuk pala kartal koşuyolu araştırma yüksek İhtisas eğitim ve hastanesi

PERKÜTAN MİTRAL KAPAK TAMİRİEndikasyonlar ve Klinik Çalışmalar

kapak tamir atölyesi1-2 Kasım 2013, İSTANBUL

Dr. Selçuk PalaKartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi

European Heart Journal (2007) 28, 1358–1365

EVEREST I(Endovascular Valve Edge-to-Edge Repair)

inclusion criteria • All patients were potential candidates for MV surgery

• symptomatic and/or had compromised LV function(LVEF <60% or LVESD >45 mm).

• With regard to MR severity, patients met at least three out of six criteria for severity, one of which was quantitative.

EVEREST I exclusion criteria

• Etiology of MR being infectious or rheumatic • LVEF of <30%• LVES dimension of >55 mm• MV area of <4.0 cm2

EVEREST I

EVER

EST

II

EVER

EST

II

EVER

EST

II

EVEREST II

EVEREST II

EVEREST II

EVER

EST

II

EVEREST II

EVEREST II

EVEREST II

EVEREST II

EVEREST II HRR

EVEREST II comparator group (n= 36)

EVEREST HRS

EVEREST II HRS

EVEREST HRS

ACCESS EU

ACCESS EU

ACCESS EU

ACCESS EU

ESC

SUMMARY

• The MitraClip procedure can be performed safely with low major advers event rate.

• Beyond 6 months, the rate of MV surgery low in the MitraClip patients

SUMARY

• SURGERY İS the standard of care for treatment of MR among elegible patient

SUMMARY

• Clinical benefits provided by MitraClip is durable through 4 years

** Reduced in MR severity ** İmprovment in LV Dimension ** İmprovments in NYHA Functional Class

Conclusion

The MitraClip procedure is a therapeutic option for selected patients with significant MR

PERKÜTAN MİTRAL KAPAK TAMİRİEndikasyonlar ve Klinik Çalışmalar

kapak tamir atölyesi1-2 Kasım 2013, İSTANBUL

Dr. Selçuk PalaKartal Koşuyolu Araştırma Yüksek İhtisas Eğitim ve Hastanesi